Apellis Pharmaceuticals Inc (NAS:APLS)
$ 28.075 -0.485 (-1.7%) Market Cap: 3.49 Bil Enterprise Value: 3.59 Bil PE Ratio: 0 PB Ratio: 12.94 GF Score: 42/100

Apellis Pharmaceuticals Inc at Needham Healthcare Conference (Virtual) Transcript

Apr 11, 2022 / 07:00PM GMT
Release Date Price: $53.42 (-1.55%)
Joseph Robert Stringer
Needham & Company, LLC, Research Division - Senior Analyst

Good afternoon, everyone. Thank you for joining the 21st Annual Needham Healthcare Conference. My name is Joey Stringer, and I'm one of the biotech analysts at Needham & Company. It's my pleasure to introduce our next presenting company, Apellis Pharmaceuticals.

Joining us today from Apellis is Co-Founder, President and CEO, Cedric Francois. For those of you joining on the webcast, if you want to ask a question, please do so at any time. You can submit a question using the chat box at the bottom of your screen.

With that, we'll go ahead and get started. I'll turn it over to Cedric for some opening remarks, and then we'll go ahead and start the chat.

Cedric Francois
Apellis Pharmaceuticals, Inc. - Co-Founder, President, CEO & Director

Well, thank you, Joey, for inviting us, and it's a pleasure to be at this meeting. Still virtually. Soon, we'll do all of this in-person again, I hope. But a few words about Apellis for those of you are less familiar

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot